Results 271 to 280 of about 482,699 (357)

Four cases of oral cancer treated with adoptive immunotherapy (LAK therapy) and radiotherapy.

, 1996
湯川 善弘, 笹倉 裕一, 小瀬 晃, 篠塚 和明, 松本 剛一, 小堀 実, 伊吹 千夏, 李 宇錫, 新藤 潤一, 渡辺 是久   +9 more
openalex   +2 more sources

Adjuvant treatment of colorectal cancer: towards tumor-specific immunotherapies. [PDF]

, 2001
AJM van den Eertwegh, Arnold Baars, HM Pinedo   +2 more
openalex   +1 more source

ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapy. [PDF]

Bioinformatics
Shraim R, Mooney B, Conkrite KL, Hamilton AK, Morin GB, Sorensen PH, Maris JM, Diskin SJ, Sacan A.   +8 more
europepmc   +1 more source

Conjugated Lithocholic Acid Activates Hepatic TGR5 to Promote Lipotoxicity and MASLD‐MASH Transition by Disrupting Carnitine Biosynthesis

Advanced Science, EarlyView.
Takeda G protein‐coupled receptor 5 (TGR5) serves as a central regulator in the metabolic dysfunction‐associated steatotic liver disease (MASLD)/metabolic dysfunction‐associated steatohepatitis (MASH) transition via conjugated lithocholic acid (LCA). Mechanistically, TGR5 orchestrates lipotoxicity‐induced cell death through its interaction with CD36 ...
Senlin Lian, Meixi Lu, Luo Jiajing, Bin Zhang, Yi Fang, Xuran Wang, Minghua Zheng, Yan Ni, Guifang Xu, Yonglin Yang, Runqiu Jiang   +10 more
wiley   +1 more source

Progress in the development of immunotherapy for the treatment of patients with cancer [PDF]

, 2001
Steven A. Rosenberg
openalex   +1 more source

CAR-macrophages: tailoring cancer immunotherapy. [PDF]

Front Immunol
Chettri D, Satapathy BP, Yadav R, Uttam V, Jain A, Prakash H.   +5 more
europepmc   +1 more source

Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer

Advanced Science, EarlyView.
This study introduces a tumor‐targeted nanomicelle platform (preS1‐pHLIP) that exploits pre‐existing antiviral immunity to combat heterogeneous cancers. By delivering viral antigens to label tumors as virus‐like targets, the nanomicelles activate antiviral B and T cells, triggering in situ tumor lysis.
Lizhuo Zhang, Qingqing Feng, Chuanming Zheng, Yuanqiang Li, Xinyang Ge, Tiefeng Jin, Gaofeng Hu, Zhuo Tan, Jiafeng Wang, Jiajie Xu, Liehao Jiang, Dan Wang, Zhangguo Ying, Xiao Zhao, Keman Cheng, Qinglin Li, Minghua Ge   +16 more
wiley   +1 more source

Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy. [PDF]

Clin Transl Sci
Srikanth G, Beda DP, Dwivedi AR, Duddukuri NK, Nanduri S, Patel J.   +5 more
europepmc   +1 more source

Chemotherapy‐Mediated Induction of PD‐L1 via SEI1 Facilitates Myeloma Immune Evasion

Advanced Science, EarlyView.
Chemotherapy induces DNA damage, activating cyclic guanosine monophosphate (GMP)‐adenosine monophosphate (AMP) synthase (cGAS)/stimulator of interferon genes (STING), which phosphorylates interferon regulatory factor 7 (IRF7) to drive SERTA‐containing domain 1 (SEI1) transcription.
Rui Chen, Zongwei Li, Zhihong Fang, Zou Li, Daoyan Yang, Yuan Li, Shurong Liu, Zhiqiang Liu, Rui Liu, Huan Liu   +9 more
wiley   +1 more source

IL-27: overclocking cytotoxic T lymphocytes to boost cancer immunotherapy. [PDF]

Signal Transduct Target Ther
Dusi S, Bronte V, De Sanctis F.
europepmc   +1 more source